Conatus Pharmaceuticals Inc (CNAT) Given Average Recommendation of “Buy” by Brokerages
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) has received an average recommendation of “Buy” from the nine ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $14.50.
Several research firms have issued reports on CNAT. Aegis reissued a “buy” rating and set a $11.00 target price on shares of Conatus Pharmaceuticals in a research note on Monday, May 15th. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Conatus Pharmaceuticals in a research note on Thursday, June 29th. Zacks Investment Research cut Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Finally, ValuEngine raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 24th.
A number of large investors have recently bought and sold shares of CNAT. Bank of Montreal Can acquired a new stake in Conatus Pharmaceuticals during the second quarter valued at about $109,000. Courage Capital Management LLC boosted its stake in Conatus Pharmaceuticals by 25.0% in the first quarter. Courage Capital Management LLC now owns 125,000 shares of the biotechnology company’s stock valued at $721,000 after buying an additional 25,000 shares during the period. Renaissance Technologies LLC boosted its stake in Conatus Pharmaceuticals by 28.1% in the first quarter. Renaissance Technologies LLC now owns 235,290 shares of the biotechnology company’s stock valued at $1,358,000 after buying an additional 51,590 shares during the period. Bank of New York Mellon Corp boosted its stake in Conatus Pharmaceuticals by 2.1% in the first quarter. Bank of New York Mellon Corp now owns 80,310 shares of the biotechnology company’s stock valued at $464,000 after buying an additional 1,655 shares during the period. Finally, Acadian Asset Management LLC acquired a new stake in Conatus Pharmaceuticals during the first quarter valued at about $854,000. 18.84% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/07/18/conatus-pharmaceuticals-inc-cnat-given-average-recommendation-of-buy-by-brokerages-3.html.
Conatus Pharmaceuticals (NASDAQ:CNAT) opened at 6.39 on Tuesday. The stock’s market cap is $167.22 million. The company’s 50-day moving average price is $5.22 and its 200-day moving average price is $5.27. Conatus Pharmaceuticals has a 12-month low of $1.45 and a 12-month high of $9.40.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.20. Conatus Pharmaceuticals had a negative return on equity of 70.45% and a negative net margin of 51.77%. The firm had revenue of $7 million during the quarter, compared to analysts’ expectations of $5.88 million. During the same quarter last year, the firm earned ($0.35) earnings per share. On average, equities analysts expect that Conatus Pharmaceuticals will post ($0.71) EPS for the current fiscal year.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.